- Home
- ASRT vs CYCC Comparison
ASRT vs CYCC Comparison
Compare ASRT & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- CYCC
- Stock Information
- Founded
- ASRT 1995
- CYCC 1992
- Country
- ASRT United States
- CYCC Malaysia
- Employees
- ASRT N/A
- CYCC N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- CYCC Health Care
- Exchange
- ASRT Nasdaq
- CYCC Nasdaq
- Market Cap
- ASRT 57.9M
- CYCC 47.6M
- IPO Year
- ASRT 1997
- CYCC N/A
- Fundamental
- Price
- ASRT $0.61
- CYCC $0.25
- Analyst Decision
- ASRT Strong Buy
- CYCC Strong Buy
- Analyst Count
- ASRT 3
- CYCC 1
- Target Price
- ASRT $3.08
- CYCC $11.00
- AVG Volume (30 Days)
- ASRT 305.8K
- CYCC 7.3M
- Earning Date
- ASRT 05-12-2025
- CYCC 05-20-2025
- Dividend Yield
- ASRT N/A
- CYCC 59.13%
- EPS Growth
- ASRT N/A
- CYCC N/A
- EPS
- ASRT N/A
- CYCC N/A
- Revenue
- ASRT $124,961,000.00
- CYCC $43,000.00
- Revenue This Year
- ASRT N/A
- CYCC $137.21
- Revenue Next Year
- ASRT $11.20
- CYCC N/A
- P/E Ratio
- ASRT N/A
- CYCC N/A
- Revenue Growth
- ASRT N/A
- CYCC N/A
- 52 Week Low
- ASRT $0.51
- CYCC $0.17
- 52 Week High
- ASRT $1.80
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- ASRT 43.47
- CYCC 47.06
- Support Level
- ASRT $0.58
- CYCC $0.28
- Resistance Level
- ASRT $0.66
- CYCC $0.37
- Average True Range (ATR)
- ASRT 0.05
- CYCC 0.07
- MACD
- ASRT 0.00
- CYCC 0.01
- Stochastic Oscillator
- ASRT 23.53
- CYCC 20.67
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.